FOSTER CITY, Calif.--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced today the appointment of Bryan Yoon as Chief Operating Officer and General Counsel.
“Bryan brings significant operational, strategic, and legal expertise as well as life sciences experience to Terns, adding further strength to our executive team,” said Senthil Sundaram, Chief Executive Officer of Terns. “We are pleased to welcome Bryan at this exciting time as we grow the company and advance our NASH pipeline with multiple ongoing and upcoming clinical trials of our farnesoid X receptor (FXR) agonist, our vascular adhesion protein-1 (VAP-1) inhibitor, and our thyroid hormone receptor beta (THR-β) agonist.”
Mr. Yoon commented, “NASH is an area of high unmet need with no approved therapies. I am pleased to join a strong team dedicated to advancing a broad pipeline of drug candidates targeting clinically validated mechanisms in NASH. I look forward to working with Senthil and the rest of the Terns team towards our goal of delivering best-in-class therapies to NASH patients.”
Mr. Yoon will be a part of the executive team and will be responsible for corporate strategy, business development, and certain corporate operational functions, including human resources, legal, and compliance. Prior to becoming Chief Operating Officer and General Counsel at Terns, Mr. Yoon served as the Chief Administrative Officer, General Counsel, and Secretary of LogicBio Therapeutics. Before that, he served as the General Counsel and Secretary of Nightstar Therapeutics, plc, until its acquisition by Biogen in June 2019. Prior to joining Nightstar, Mr. Yoon held roles of increasing responsibility at Intercept Pharmaceuticals, Inc., a publicly trade biotechnology company, where he most recently was Senior Vice President, Legal Affairs and Secretary. Mr. Yoon received his undergraduate degree in Economics and Master of Engineering from Cornell University, and his J.D. from University of Michigan Law School.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns’ investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.
